MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases, and Helix Acquisition have entered into a definitive business combination agreement.
If approved, upon closing MoonLake is expected to list on the Nasdaq under MLTX.
The combined enterprise is expected to have an implied pro forma equity value of approximately $620 million at closing.
In addition to the $115 million held in Helix Acquisition’s trust (assuming no redemptions), the transaction also includes commitments for a $115 million PIPE led by the SPAC’s sponsor Cormorant Asset Management, and includes BVF Partners, 683 Capital Partners, Asymmetry Capital Management, funds managed by Ghost Tree Capital Group, Monashee Investment Management, RTW Investments, Surveyor Capital, TCG X and funds managed by Tekla Capital Management. Read more.
